Vinorelbine tartrate

Molecular Weight：1079.119

Modify Date.: 2023-03-29 08:03

Introduction: Vinorelbine ditartrate is available in 1- and 5-mL vials at aconcentration of 10 mg/mL for IV use. It is FDA approvedfor the treatment of NSCLC. The agent has also been usedin treating metastatic breast cancer, cervical cancer, uterinecancer, and lung cancer especially in older patients or thosewith physical difficulties. Vinorelbine is the most lipophilicof the vinca alkaloids because of modifications of thecatharanthine ring system and dehydration of the piperidinering. This allows the agent to be quickly taken up into cellsincluding lung tissue where concentrations are 300-foldhigher than plasma concentrations. This is 3 to 13 timeshigher than the lung concentrations seen with vincristine.The agent is highly protein bound (80%–91%) and metabolizedby CYP3A. The major metabolite seen is the 4-Odesacetylderivative, which is equally active with the parentbut only formed in small quantities. The agent is eliminatedprimarily (33%–88%) in the bile with some appearing inthe urine (16%–30%). The elimination half-life is 27 to43 hours. The toxicities seen for vinorelbine includemyelosuppression, which is dose limiting but ceases upondiscontinuation of drug. This is most commonly seen as aneutropenia, and patient’s neutrophil count should be monitoredprior to and during therapy to decrease the chanceof infection. Additional toxicities include nausea/vomiting,elevation of liver function tests, alopecia, generalized fatigue，and inappropriate secretion of antidiuretic hormone.Neurotoxicity is seen with vinorelbine but occurs to a lesserdegree compared with other vinca alkaloids because of itsdecreased affinity for axonal microtubules. View more+

Request For Quotation

1. Names and Identifiers

1.1 Name: Vinorelbine tartrate
1.2 Synonyms: (2R,3R)-2,3-Dihydroxysuccinic acid - methyl (2β,3β,4β,5α,12β,19α)-4-acetoxy-15-[(12R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8, 15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate (2:1) 2,3-Dihydroxybutandisäure-methyl-(3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-5-hydroxy-8-methoxy-6-methyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazol-5-carboxylat(2:1) 3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine (R-(R*,R*))-2,3-dihydroxybutanedioate (1:2) (salt) 3′,4′-Didehydro-4′-deoxy-C′-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt], 5′-Noranhydrovinoblastine tartrate, KW-2307, NVB, Navelbine tartrate 6-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate bis(2,3-dihydroxybutanedioate) (salt) -6-methyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate bis(2,3-dihydroxybutanedioate) (salt) acide 2,3-dihydroxybutanedioïque - (3aR,4R,5S,5aR,10bR,13aR)-4-(acétyloxy)-3a-éthyl-9-[(12S,14R)-16-éthyl-12-(méthoxycarbonyl)-1,10-diazatétracyclo[12.3.1.0.0]octadéca-3(11),4,6,8,15-pentaén-12-yl]-5-hydroxy-8-méthoxy-6-méthyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate de méthyle (2:1) Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, m aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2Β,3Β,4Β,5α,12Β,19α)-, 2,3-dihydroxybutanedioate (1:2) (salt) Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(8R)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, meth Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl es ter aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester butanedioate(1:2) ethyl ester, (2Β,3Β,4Β,5α,12Β,19α)-, 2,3-dihydroxybutanedioate (1:2) (salt) Eunades methyl (2Β,3Β,4Β,5α,12Β,19α)-4-(acetyloxy)-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-1 methyl (2Β,3Β,4Β,5α,12Β,19α)-4-(acetyloxy)-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate bis(2,3-dihydroxybutanedioate) (salt) methyl (2Β,3Β,4Β,5α,12Β,19α)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate 2,3-dihydroxybutanedioate (1:2) Methyl (2Β,3Β,4Β,5α,12Β,19α)-4-acetoxy-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate 2,3-dihydroxysuccinate (1:2) Methyl (2Β,3Β,4Β,5α,12Β,19α)-4-acetoxy-15-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate bis(2,3-dihydroxysuccinate) (salt) methyl (3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-5-hydroxy-8-methoxy methyl (3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-5-hydroxy-8-methoxy-6-methyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate bis(2,3-dihydroxybutanedioate) (salt) Methyl (3aR,4R,5S,5aR,10bR,13aR)-4-acetoxy-3a-ethyl-9-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0.0]octadeca-3(11),4,6,8,15-pentaen-12-yl]-5-hydroxy-8-methoxy-6-methyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate bis(2,3-dihydroxysuccinate) (salt) methyl 4-(acetyloxy)-15-[4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate Methyl 4-acetoxy-15-[16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carbo MFCD03613607 Nor-5'-anhydrovinblastine ditartrate thoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate 2,3-dihydroxysuccinate (1:2) Vinorelbine Vinorelbine (ditartrate) VINORELBINE BASE Vinorelbine Ditartarate Vinorelbine ditartrate Vinorelbine ditartrate salt VINORELBINE RELATED COMPOUND A4-O-DEACETYLVINORELBINE TARTRATE USP STANDARD VINORELBINE TARTRATE USP STANDARD VINORELBINE TARTRATE, NAVELBINE VINORELBINE TARTRATE, USP VINORELBINEDITARTRATE SALT HYDRATE VinorelbineTartrateUsp28 xylate yl ester, (2β,3β,4β,5α,12β,19α)-, compd. with (2R,3R)-2,3-dihydroxybutanedioic acid (1:2)

1.3 CAS No.: 125317-39-7

1.4 CID: 11607738

1.5 EINECS(EC#): 1806241-263-5

1.6 Molecular Formula: C53H66N4O20 (isomer)

1.7 Inchi: InChI=1S/C45H54N4O8.2C4H6O6/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7;2*5-1(3(7)8)2(6)4(9)10/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3;2*1-2,5-6H,(H,7,8)(H,9,10)/t28-,37-,38+,39+,42+,43+,44-,45-;2*1-,2-/m011/s1

1.8 InChIkey: CILBMBUYJCWATM-PYGJLNRPSA-N

1.9 Canonical Smiles: CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC.C(C(C(=O)O)O)(C(=O)O)O.C(C(C(=O)O)O)(C(=O)O)O

1.10 Isomers Smiles: CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O

2. Properties

2.1 Density: 1.36

2.1 Melting point: 181-183°C

2.1 Refractive index: 1.675

2.1 Precise Quality: 1078.43000

2.1 PSA: 363.99000

2.1 logP: 0.44920

2.1 Solubility: H2O: 10?mg/mL

2.2 Appearance: white to off-white crystalline powder

2.3 Chemical Properties: White or almost white powder or crystalline powder, odorless.

2.4 Color/Form: off-white

2.5 Water Solubility: H2O: 10?mg/mL

2.6 StorageTemp: 2-8°C

3. Use and Manufacturing

3.1 Definition: ChEBI: The L-(+)-tartrate salt of vinorelbine.

3.2 GHS Classification: Signal: Danger
GHS Hazard Statements
Aggregated GHS information provided by 41 companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

H301 (92.68%): Toxic if swallowed [Danger Acute toxicity, oral]
H315 (97.56%): Causes skin irritation [Warning Skin corrosion/irritation]
H319 (97.56%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
H341 (95.12%): Suspected of causing genetic defects [Warning Germ cell mutagenicity]
H360 (100%): May damage fertility or the unborn child [Danger Reproductive toxicity]
H372 (90.24%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]

Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.

Precautionary Statement Codes
P201, P202, P260, P264, P270, P280, P281, P301+P310, P302+P352, P305+P351+P338, P308+P313, P314, P321, P330, P332+P313, P337+P313, P362, P405, and P501

3.3 Usage: An antineoplastic

4. Safety and Handling

4.1 Hazard Codes: Xi

4.1 Risk Statements: R43

4.1 Safety Statements: S26;S36

4.1 RIDADR: OTH

4.1 WGK Germany: 3

4.1 Safety: Experimental reproductive effects. When heated to decomposition it emits toxic vapors of NO_x.
Hazard Codes:? Xi
The Risk Statements information:
43:? May cause sensitization by skin contact?
The Safety Statements information:
26:? In case of contact with eyes, rinse immediately with plenty of water and seek medical advice?
36:? Wear suitable protective clothing?
WGK Germany: 3

4.2 Specification: ?Vinorelbine tartrate , with CAS number of 125317-39-7, can be called Vinorelbine ditartrate ; Nor-5'-anhydrovinblastine ditartrate ; C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:2) (salt) ; 3',4'-Didehydro-4'-deoxy-8'-norvincaleukoblastine L-(+)-tartrate (1:2) (salt) .

4.3 Toxicity

???

ivn-rat TDLo:2?mg/kg (female 7-16D post):REP

???

KSRNAM ?? Kiso to Rinsho. Clinical Report. 27 (1993),1375.

5. MSDS

2.Hazard identification

2.1 Classification of the substance or mixture

Acute toxicity - Oral, Category 3

Skin irritation, Category 2

Eye irritation, Category 2

Germ cell mutagenicity, Category 2

Reproductive toxicity, Category 1B

Specific target organ toxicity \u2013 repeated exposure, Category 1

2.2 GHS label elements, including precautionary statements

Pictogram(s)
Signal word	Danger
Hazard statement(s)	H301 Toxic if swallowed H315 Causes skin irritation H319 Causes serious eye irritation H341 Suspected of causing genetic defects H360 May damage fertility or the unborn child H372 Causes damage to organs through prolonged or repeated exposure
Precautionary statement(s)
Prevention	P264 Wash ... thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves/protective clothing/eye protection/face protection. P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust/fume/gas/mist/vapours/spray.
Response	P301+P310 IF SWALLOWED: Immediately call a POISON CENTER/doctor/\u2026 P321 Specific treatment (see ... on this label). P330 Rinse mouth. P302+P352 IF ON SKIN: Wash with plenty of water/... P332+P313 If skin irritation occurs: Get medical advice/attention. P362+P364 Take off contaminated clothing and wash it before reuse. P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337+P313 If eye irritation persists: Get medical advice/attention. P308+P313 IF exposed or concerned: Get medical advice/ attention. P314 Get medical advice/attention if you feel unwell.
Storage	P405 Store locked up.
Disposal	P501 Dispose of contents/container to ...

2.3 Other hazards which do not result in classification

none

View all

6. NMR Spectrum

Predict 1H proton NMR

7. Other Information

7.0 Overview: Vinorelbine belongs to vinblastine derivatives, its action is similar to vincristine. It is first marketed in 1989 in France. The main role is to combine tubulin, consequently, it causes microtubule formation disorder during cells mitosis.
Vinorelbine belongs to cycle specific drugs, it is used clinically in the treatment of non-small cell lung cancer (NSCLC) and breast cancer, ovarian cancer, head and neck squamous cell carcinoma, leukemia. In addition,it also has a strong inhibitory effect on small cell lung cancer, colon cancer, brain tumors, malignant melanoma.

7.1 Pharmacological effects: Vinorelbine tartrate is the tartrate form of vinorelbine ,it is a semi-synthetic vincristine compound, it belongs to M phase specific drugs, mechanism of action is similar to vincristine . Mainly it , by selectively blocking mitotic cell tubulin polymerization to form microtubule and inducing tubulin depolymerization , impedes spindle microtubules,and it makes cell division stop in the middle, and it has few effect on the synthetic tubulin in the shaft of nerve cells. Since NVB affinity for axonal microtubules is poor, only when there is a high concentration of it ,it has effect on axonal , so it has the lower neurotoxicity than other vincristine drugs,and it has a greater therapeutic index. Human pharmacokinetics of vinorelbine show that after intravenous administration there is a three-compartment model, the volume of distribution is large , PPB is up to 50% to 80%, plasma clearance rate is high, the terminal elimination phase T1/2 is 40 h, it has a rapid tissue distribution, concentration in tissues is significantly higher than vincristine (VCR), vindesine (VDS). Plasma clearance is 0.8 L/(kg ? h),it is mainly through biliary secretion, and it is excreted with the feces, urine excretion accounts for 10% to 15%.It has a higher efficacy and less adverse reactions of the nervous system.

7.2 Clinical evaluation: Numerous clinical studies have shown that vinorelbine is one of the most effective drugs for the treatment of non-small cell lung cancer and breast cancer, single agent response rate is 14% to 35% and 30% to 60% respectively. And DDP combination chemotherapy in NSCLC and with doxorubicin combination therapy of breast cancer, efficiency is up to 30% to 50% and 50% to 77%, respectively. It has a good effect on ovarian cancer, malignant lymphoma, head and neck cancer, esophageal cancer.

7.3 Adverse reactions

Vinorelbine hematologic toxicity is dose-limiting , mainly it is neutropenia, which mostly restore within 7d, it has a certain influence on red blood cells , thrombocytopenia and anemia incidence is less than 2%.
Neurotoxicity mainly performs as tendon reflexes (about 25%), occasional paresthesia, few patients may have gastrointestinal autonomic nerve paralysis induced constipation (17%~41%), paralytic ileus is rare , 2% 6% of the patients suffer finger (toe) numb, but the incidence is much lower than the VCR and VDS.
Incidence of gastrointestinal side effects is less than 10%. Occasionally, nausea, vomiting, dyspnea, and bronchospasm, often occur in a few minutes or several hours after treatment . Alopecia incidence is less than 10%.
Vinorelbine drug extravasation into the surrounding tissue can cause burning, injection site phlebitis, local tissue necrosis, ulceration, cellulitis.
Myelosuppression is dose-limiting toxicity. 3 to 5 days after the medication, transient myelosuppression can occur, usually it can recover within 10 days, attention should be paid to prevent infection. Neurotoxicity is visible.

View all

7.4 Chemical properties: White or almost white powder or crystalline powder, odorless.

7.5 Application: Antineoplastic agents

7.6 Chemical Properties: Pale Yellow Powder

7.7 Uses: An antineoplastic

7.8 Definition: ChEBI: The L-(+)-tartrate salt of vinorelbine.

7.9 Brand name: Navelbine (Pierre).

7.10 Biological Activity: Selective mitotic microtubule antagonist that exhibits > 20 fold selectivity over axonal microtubules. Inhibits proliferation of multiple human tumor cell lines (IC 50 = 1.25 nM in HeLa cells) and blocks metaphase/anaphase transition by suppression of microtubule dynamics (IC 50 = 3.8 nM). Reduces spindle length by 29% and inhibits microtubule polymerization at micromolar concentrations.

7.11 Uses: Vinorelbine Bitartrate is an antineoplastic.

7.12 General Description: Vinorelbine ditartrate is available in 1- and 5-mL vials at aconcentration of 10 mg/mL for IV use. It is FDA approvedfor the treatment of NSCLC. The agent has also been usedin treating metastatic breast cancer, cervical cancer, uterinecancer, and lung cancer especially in older patients or thosewith physical difficulties. Vinorelbine is the most lipophilicof the vinca alkaloids because of modifications of thecatharanthine ring system and dehydration of the piperidinering. This allows the agent to be quickly taken up into cellsincluding lung tissue where concentrations are 300-foldhigher than plasma concentrations. This is 3 to 13 timeshigher than the lung concentrations seen with vincristine.The agent is highly protein bound (80%–91%) and metabolizedby CYP3A. The major metabolite seen is the 4-Odesacetylderivative, which is equally active with the parentbut only formed in small quantities. The agent is eliminatedprimarily (33%–88%) in the bile with some appearing inthe urine (16%–30%). The elimination half-life is 27 to43 hours. The toxicities seen for vinorelbine includemyelosuppression, which is dose limiting but ceases upondiscontinuation of drug. This is most commonly seen as aneutropenia, and patient’s neutrophil count should be monitoredprior to and during therapy to decrease the chanceof infection. Additional toxicities include nausea/vomiting,elevation of liver function tests, alopecia, generalized fatigue，and inappropriate secretion of antidiuretic hormone.Neurotoxicity is seen with vinorelbine but occurs to a lesserdegree compared with other vinca alkaloids because of itsdecreased affinity for axonal microtubules.

7.13 Biological Activity: Selective mitotic microtubule antagonist that exhibits > 20 fold selectivity over axonal microtubules. Inhibits proliferation of multiple human tumor cell lines (IC 50 = 1.25 nM in HeLa cells) and blocks metaphase/anaphase transition by suppression of microtubule dynamics (IC 50 = 3.8 nM). Reduces spindle length by 29% and inhibits microtubule polymerization at micromolar concentrations.

7.14 Biochem/physiol Actions: Vinorelbine is a potent anti-mitotic, anti-tumor agent. Vinorelbine inhibits microtubule assembly. Low neurotoxicity is related to its higher affinity for mitotic microtubules than for axonal microtubules.

8. Computational chemical data

Molecular Weight: 1079.119g/mol
Molecular Formula: C₅₃H₆₆N₄O₂₀
Compound Is Canonicalized: True
XLogP3-AA: null
Exact Mass: 1078.42704051
Monoisotopic Mass: 1078.42704051
Complexity: 1820
Rotatable Bond Count: 16
Hydrogen Bond Donor Count: 10
Hydrogen Bond Acceptor Count: 23
Topological Polar Surface Area: 364
Heavy Atom Count: 77
Defined Atom Stereocenter Count: 12
Undefined Atom Stereocenter Count: 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Isotope Atom Count: 0
Covalently-Bonded Unit Count: 3
CACTVS Substructure Key Fingerprint: AAADcfB/vgAAAAAAAAAAAAAAAAAAAWLFgAAwYMECAAAWAFiB9AAAHgAQCAAAD3zhngYyzvPJlgCoAyTyTAKCiCAhIiAImSF+bJgPNv7E9ZuGcChn8Bnb6Af72fOfqAACAgAKAABQgAYECBSgAAAAAAAAAA==

9. Recommended Suppliers

Global270SuppliersView all >>

Wuhan Fortuna Chemical Co., Ltd. Diamond member

-113YR

Products:API,fine chemical&its intermediates,biological chemistry
Tel:0086-27-59207850
Email:info@fortunachem.com

Vinorelbine tartrate CAS 125317-39-7

Purity:99%Packing: 200kg/bag FOB
Price: 10 USD/kg
Time: 2023/06/05

Inquire

Jinlan Pharm-Drugs Technology Co., Limited Diamond member

-112YR

Products:Veterinary products,Nutrition products,Agrochemicals,Active pharmaceutical Ingredients,Custom systhesis,Contract manufacturing
Tel:86-571-85829052
Email:market@royalpharms.com

Vinorelbine Ditartrate